Get the Stockscreener App
9.46
0.11%
0.01
Pre-market:
9.64
0.18
+1.90%
Biohaven Ltd stock is traded at $9.46, with a volume of 3.89M.
It is up +0.11% in the last 24 hours and down -40.69% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$9.45
Open:
$9.24
24h Volume:
3.89M
Relative Volume:
1.13
Market Cap:
$1.00B
Revenue:
-
Net Income/Loss:
$-766.97M
P/E Ratio:
-1.235
EPS:
-7.66
Net Cash Flow:
$-646.43M
1W Performance:
+18.99%
1M Performance:
-40.69%
6M Performance:
-39.94%
1Y Performance:
-79.57%
1-Day Range:
$8.95
$9.495
1-Week Range:
$7.78
$9.70
52-Week Range:
$7.48
$47.75
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
9.46 | 1.25B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.03 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.75 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.76 | 61.08B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
914.59 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.56 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
How Biohaven Ltd. stock reacts to inflationary pressuresOptions Play & AI Powered Market Entry Strategies - newser.com
Can Biohaven Ltd. Common Shares stock sustain double digit ROEJuly 2025 Fed Impact & AI Driven Price Forecasts - newser.com
Is Biohaven Ltd. stock vulnerable to regulatory risks2025 Top Gainers & AI Enhanced Trading Alerts - newser.com
Is Biohaven Ltd. Common Shares stock undervalued historicallyJuly 2025 Closing Moves & Safe Entry Point Identification - newser.com
Should I buy Biohaven Ltd. Common Shares stock before earnings season2025 EndofYear Setup & Intraday High Probability Alerts - newser.com
What MACD trends signal for Biohaven Ltd. Common Shares stockPortfolio Profit Report & High Win Rate Trade Alerts - newser.com
What Fibonacci levels say about Biohaven Ltd. rebound2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
Building trade automation scripts for Biohaven Ltd.July 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy? - The Motley Fool
Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy? - The Motley Fool
Signal strength of Biohaven Ltd. stock in tech scanners2025 Top Gainers & Risk Controlled Daily Trade Plans - newser.com
Can Biohaven Ltd. stock resist sector downturnsJuly 2025 Recap & Pattern Based Trade Signal System - newser.com
Has Biohaven Ltd. formed a bullish divergenceJuly 2025 Chart Watch & Low Drawdown Investment Ideas - newser.com
Why Biohaven Ltd. stock is favored by pension fundsJuly 2025 Levels & Low Drawdown Momentum Ideas - newser.com
Independent Director of Biohaven John Childs Buys 52% More Shares - simplywall.st
William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth - MSN
Market reaction to Biohaven Ltd.’s recent newsJuly 2025 WrapUp & Advanced Swing Trade Entry Plans - newser.com
Will Biohaven Ltd. stock reach Wall Street targetsMarket Performance Recap & Growth Oriented Trading Recommendations - newser.com
Top Executive Makes Major Stock Purchase in Biohaven Ltd. - TipRanks
Why hedge funds are buying Biohaven Ltd. stock2025 Price Action Summary & Verified Momentum Stock Ideas - newser.com
Biohaven Ltd. (BHVN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Strategic Adjustments and Future Potential: Biohaven Ltd. Receives Buy Rating Amidst Regulatory Challenges - TipRanks
Hedge Fund and Insider Trading News: Bill Ackman, Michael Burry, Marshall Wace, Armistice Capital, Exploration Capital, Zweig-DiMenna, Biohaven Ltd (BHVN), and More - Insider Monkey
Biohaven raises about $200M in public offering - Hartford Business Journal
Biohaven price target lowered to $26 from $54 at Morgan Stanley - TipRanks
Is a relief rally coming for Biohaven Ltd. holdersMarket Performance Recap & Stock Portfolio Risk Management - newser.com
Biohaven (BHVN) VP Clark buys $144k in company stock By Investing.com - Investing.com South Africa
Biohaven (BHVN) VP Clark buys $144k in company stock - Investing.com
Strategic Positioning and Growth Potential Drive Buy Rating for Biohaven Ltd. - TipRanks
Will Biohaven Ltd. stock gain from strong economyTrade Risk Summary & Daily Stock Trend Watchlist - newser.com
Biohaven Ltd. Executives Make Massive Stock Purchases! - TipRanks
Does Biohaven Ltd. fit your quant trading model2025 Risk Factors & High Win Rate Trade Alerts - newser.com
Biohaven (BHVN) Price Target Decreased by 45.07% to 25.95 - Nasdaq
Biohaven Ltd. Stock (BHVN) Opinions on Insider Buying and Public Offering - Quiver Quantitative
Morgan Stanley cuts Biohaven stock price target to $26 on FDA setback - Investing.com Nigeria
Insider Buying: Gregory Bailey Acquires 400,000 Shares of Biohav - GuruFocus
Biohaven Insider Bought Shares Worth $24,999,998, According to a Recent SEC Filing - MarketScreener
Biohaven Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing - MarketScreener
How Biohaven Ltd. Common Shares stock trades in high volatilityMarket Movers & Fast Entry High Yield Tips - newser.com
Vlad Coric, Biohaven CEO, buys $5m in BHVN stock By Investing.com - Investing.com Australia
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):